Dr. Rami Komrokji, MD
Claim this profileMoffitt Cancer Center
Studies Myelodysplastic Syndrome
Studies Acute Myelogenous Leukemia
14 reported clinical trials
18 drugs studied
Area of expertise
1Myelodysplastic Syndrome
SF3B1 positive
ZRSR2 positive
U2AF1 positive
2Acute Myelogenous Leukemia
Affiliated Hospitals
Clinical Trials Rami Komrokji, MD is currently running
Venetoclax + CLAG-M
for AML
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
Recruiting1 award Phase 26 criteria
Epoetin Alfa vs Luspatercept
for Myelodysplastic Syndrome
This trial is testing two treatments, Luspatercept and epoetin alfa, to see which is better for treating anemia in adults with certain types of myelodysplastic syndromes (MDS). The participants have not used similar treatments before and do not need regular blood transfusions. Luspatercept helps red blood cells mature, while epoetin alfa increases their production.
Recruiting2 awards Phase 3
More about Rami Komrokji, MD
Clinical Trial Related4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Rami Komrokji, MD has experience with
- Luspatercept
- Venetoclax
- Epoetin Alfa
- Oral Azacitidine
- Placebo For Oral Azacitidine
- Quality Of Life Model
Breakdown of trials Rami Komrokji, MD has run
Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Anemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rami Komrokji, MD specialize in?
Rami Komrokji, MD focuses on Myelodysplastic Syndrome and Acute Myelogenous Leukemia. In particular, much of their work with Myelodysplastic Syndrome has involved SF3B1 positive patients, or patients who are ZRSR2 positive.
Is Rami Komrokji, MD currently recruiting for clinical trials?
Yes, Rami Komrokji, MD is currently recruiting for 5 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that Rami Komrokji, MD has studied deeply?
Yes, Rami Komrokji, MD has studied treatments such as Luspatercept, Venetoclax, Epoetin Alfa.
What is the best way to schedule an appointment with Rami Komrokji, MD?
Apply for one of the trials that Rami Komrokji, MD is conducting.
What is the office address of Rami Komrokji, MD?
The office of Rami Komrokji, MD is located at: Moffitt Cancer Center, Tampa, Florida 33612 United States. This is the address for their practice at the Moffitt Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.